West Pharmaceutical signs USD 200 million loan before West Pharmaceutical stock results
Published on 10/27/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFinancing and shareholder return
- West Pharmaceutical entered a new credit agreement on October 26, 2026, including a USD 200 million term loan.
- The company declared a USD 0.26 quarterly dividend on October 19, 2026, an 18 percent increase from the prior quarter.
- West Pharmaceutical stock was trading at EUR 354.95 at 1:42 p.m. CEST at Lang & Schwarz on October 27, 2026.
- Third-quarter results are scheduled for October 29, 2026.
West Pharmaceutical entered a new credit agreement with a USD 200 million term loan on October 26, 2026, while West Pharmaceutical stock was trading at EUR 354.95 at Lang & Schwarz on October 27, 2026 at 1:42 p.m. CEST. The filing gives the company a fresh financing framework two days before its scheduled third-quarter results. According to the SEC, the agreement also provides a revolving facility of up to USD 750 million.
A new credit framework
The October 26 filing says West used part of the new borrowings to repay USD 130.0 million outstanding under its previous credit agreement. The new facility has a five-year term, and the company said proceeds may support working capital, capital expenditures, acquisitions and share repurchases, subject to the agreement's conditions.
Three dated company steps
On October 5, 2026, West announced its participation at CPHI Worldwide, where it planned to present injectable drug packaging and delivery products. On October 19, 2026, the board declared a USD 0.26 quarterly dividend, up 18 percent from USD 0.22, according to PR Newswire. On October 26, 2026, West signed the new credit agreement described in the SEC filing.
What does the financing change?
The immediate significance is flexibility rather than a new operating forecast. West generated USD 3.07 billion in fiscal-year 2025 net sales, according to PR Newswire. The filing's 3.50-to-1.0 net leverage covenant, which can rise to 4.00-to-1.0 during material acquisition periods, sets a visible boundary for that flexibility.
Dates for results and payment
West's next scheduled reporting date is October 29, 2026, according to MarketScreener. The dividend declared on October 19 is payable on November 18, 2026, to shareholders of record on November 11, 2026, according to PR Newswire.
Stock price before the report
West's new financing arrives alongside a dividend increase and an approaching earnings event, giving investors three separate figures to assess: the USD 200 million term loan, the USD 0.26 quarterly payment and the company's upcoming operating report. The stock was trading at EUR 354.95 at Lang & Schwarz on October 27, 2026 at 1:42 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of West Pharmaceutical stock.
West Pharmaceutical stock key data
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9553061055
- Ticker: WST
- Primary exchange: New York Stock Exchange
- Price Lang & Schwarz (as of October 27, 2026, 1:42 p.m. CEST): EUR 354.95
- Market capitalization: USD 27.8 billion (as of October 26, 2026)
- Sector / Industry: Medical Equipment, Supplies and Distribution
- Index membership: S&P 500
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
